logo

For the Inventor, By the Inventor

Hyogo, Japan

Takuji Mizui

This inventor holds 8 USPTO granted patents. Top assignee: Shionogi Company Limited. Active years: 1990-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takuji Mizui. Retrieved from https://idiyas.com/inventor/takuji-mizui

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 100.0

Average Co-Inventor Count = 4.4

ph-index = 4

Forward Citations = 50(Granted Patents)


Location History:

  • Hyogo, JP (1990)
  • Hygo all Of, JP (1990)
  • San Francisco, CA (US) (1992)
  • Takarazuka, JP (1995 - 1998)

Company Filing History:

goldMedal8 out of 1,001 
 
Shionogi Company Limited
 patents

Years Active: 1990-1998

Loading Chart...
8 patents (USPTO):Explore Patents
1. 5731455 - Lignan analogues, methods of preparation thereof and anti-hyperlipemic (1998-03-24),
2. 5502216 - Lignan analogues, methods of preparation thereof and anti-hyperlipemic (1996-03-26),
3. 5449814 - Lignan analogues, methods of preparation thereof and anti-hyperlipemic (1995-09-12),
4. 5420333 - Lignan analogues, methods of preparation thereof and anti-hyperlipemic (1995-05-30),
5. 5091569 - Di-tert-butyl(hydroxy)phenylthio substituted hydroxamic acid derivatives (1992-02-25),
6. 4977170 - Isoprenoidamine compounds which are useful antiulcer agents (1990-12-11),
7. 4954514 - (Di-tert-butylhydroxyphenyl)thio derivatives and antiarterioschlerosis (1990-09-04),
8. 4900749 - Isoprenoidamine compounds useful as antiulcer agents (1990-02-13),

Title: Takuji Mizui: Innovator in Anti-Hyperlipemic Agents

Introduction

Takuji Mizui is a prominent inventor based in Hyogo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-hyperlipemic agents. With a total of eight patents to his name, Mizui's work focuses on reducing cholesterol levels, which are critical in preventing arteriosclerosis.

Latest Patents

Mizui's latest patents include innovative lignan analogues and methods of preparation thereof. These compounds serve as anti-hyperlipemic agents with potent activity in reducing LDL and VLDL cholesterols. These cholesterols are known risk factors for arteriosclerosis. His inventions also demonstrate excellent antioxidant activity on LDL. The compounds are represented by specific chemical formulas, showcasing the complexity and effectiveness of his innovations.

Career Highlights

Takuji Mizui is associated with Shionogi & Company Limited, a leading pharmaceutical company. His work at Shionogi has allowed him to focus on research and development in the field of cholesterol management. His contributions have been instrumental in advancing the understanding and treatment of hyperlipidemia.

Collaborations

Mizui has collaborated with notable coworkers, including Masami Doteuchi and Sachio Mori. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Takuji Mizui's contributions to the field of pharmaceuticals, particularly in anti-hyperlipemic agents, highlight his role as a significant inventor. His innovative approaches and collaborations continue to impact the medical community positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…